These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22525569)

  • 1. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest.
    Bartus RT
    Neurobiol Dis; 2012 Nov; 48(2):153-78. PubMed ID: 22525569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.
    Bartus RT; Baumann TL; Brown L; Kruegel BR; Ostrove JM; Herzog CD
    Neurobiol Aging; 2013 Jan; 34(1):35-61. PubMed ID: 22926166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases.
    Herzog CD; Bishop KM; Brown L; Wilson A; Kordower JH; Bartus RT
    Drug Deliv Transl Res; 2011 Oct; 1(5):361-82. PubMed ID: 25788422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
    Marks WJ; Ostrem JL; Verhagen L; Starr PA; Larson PS; Bakay RA; Taylor R; Cahn-Weiner DA; Stoessl AJ; Olanow CW; Bartus RT
    Lancet Neurol; 2008 May; 7(5):400-8. PubMed ID: 18387850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?
    Bartus RT; Johnson EM
    Neurobiol Dis; 2017 Jan; 97(Pt B):156-168. PubMed ID: 27063798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.
    Bartus RT; Herzog CD; Bishop K; Ostrove JM; Tuszynski M; Kordower JH; Gasmi M
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S469-77. PubMed ID: 18267286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotrophic factor therapy for Parkinson's disease.
    Rangasamy SB; Soderstrom K; Bakay RA; Kordower JH
    Prog Brain Res; 2010; 184():237-64. PubMed ID: 20887879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
    Gasmi M; Brandon EP; Herzog CD; Wilson A; Bishop KM; Hofer EK; Cunningham JJ; Printz MA; Kordower JH; Bartus RT
    Neurobiol Dis; 2007 Jul; 27(1):67-76. PubMed ID: 17532642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAV2-neurturin (CERE-120) for Parkinson's disease.
    Hickey P; Stacy M
    Expert Opin Biol Ther; 2013 Jan; 13(1):137-45. PubMed ID: 23228025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.
    Rafii MS; Baumann TL; Bakay RA; Ostrove JM; Siffert J; Fleisher AS; Herzog CD; Barba D; Pay M; Salmon DP; Chu Y; Kordower JH; Bishop K; Keator D; Potkin S; Bartus RT
    Alzheimers Dement; 2014 Sep; 10(5):571-81. PubMed ID: 24411134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord.
    Hendriks WT; Ruitenberg MJ; Blits B; Boer GJ; Verhaagen J
    Prog Brain Res; 2004; 146():451-76. PubMed ID: 14699980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
    Kordower JH
    Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.